article Open AccessTop 1% cited

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

The Lancet Oncology · 2014 · Vol. 15(7) · pp. 700–712

Eugene D. Kwon✉(Mayo Clinic in Arizona)Charles G. Drake(Sidney Kimmel Comprehensive Cancer Center)H. I. Scher(Cornell University)Karim Fizazi(Institut Gustave Roussy)Alberto Bossi(Institut Gustave Roussy)Alfons J.M. van den Eertwegh(Amsterdam UMC Location VUmc)Michael Krainer(Vienna General Hospital)Nadine Houédé(Centre Hospitalier Universitaire de Nîmes)Ricardo Vieira SantosHakim Mahammedi(Centre Jean Perrin)Siobhan Ng(St John of God Hospital)Michele Maio(University of Siena)Fábio FrankeSanthanam SundarNeeraj Agarwal(University of Utah)Andries M. Bergman(The Netherlands Cancer Institute)Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta)Ernesto Korbenfeld(Hospital Británico de Buenos Aires)Lisa Sengeløv(Herlev Hospital)Steinbjørn Hansen(Odense University Hospital)C. Logothetis(The University of Texas MD Anderson Cancer Center)Tomasz M. Beer(Oregon Health & Science University)M. Brent McHenry(Bristol-Myers Squibb (United States))Paul Gagnier(Bristol-Myers Squibb (United States))David Liu(Bristol-Myers Squibb (United States))Winald R. Gerritsen(Radboud University Nijmegen)

View via DOI Publisher page

Prostate Cancer Treatment and Research Cancer Immunotherapy and Biomarkers Radiopharmaceutical Chemistry and ApplicationsDocetaxelMedicineProstate cancerOncologyInternal medicinePlaceboChemotherapyRadiation therapyIpilimumabClinical trial

MeSH terms

IpilimumabDocetaxelAdultAgedAntibodies, MonoclonalAntineoplastic AgentsCombined Modality TherapyDouble-Blind MethodHumansMaleMiddle AgedDisease ProgressionTaxoidsProstatic Neoplasms, Castration-Resistant

Citations

1,480

FWCI

101.40

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer